|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Formylmelphalan
|
MedKoo Code#: 100382
|
|
Name:
Formylmelphalan
|
|
CAS#: 7789-59-5
Synonym: N-Formylmelphalan;
N-Formyl-L-sarcolysin; N-Formyl-L-p-sarcolysin; CB 3208; NSC
37024; NSC37024; LS-15879; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)-N-formylalanine;
L-Alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-N-formyl-.
IUPAC/Chemical name:
3-[4-[bis(2-chloroethyl)amino]phenyl]-2-formamidopropanoic acid
|
|
Chemical structure:
|
Theoretical analysis
:
|
|
|
Chemical Formula: C14H18Cl2N2O3
Exact Mass: 332.06945
Molecular Weight: 333.210
m/z: 332.06945 (100.0%), 334.06650 (63.9%),
333.07280 (15.1%), 336.06355 (10.2%), 335.06985 (9.7%),
337.06690 (1.5%), 334.07616 (1.1%)
Elemental Analysis: C, 50.46; H, 5.44; Cl,
21.28; N, 8.41; O, 14.40
|
|
Availability and price:
For quotation, question, and order, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer significant discount
for larger quantity order.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
Formylmelphalan
was approved in China for treating cancer.
Formylmelphalan is
an alkylating agents, which could cross-link DNA.
1: Volk J, Kleine HD, Buthmann U, Freund M.
Oxidative burst measurement in patients treated with cytostatics:
influence of G-CSF and role as a prognostic factor. Ann Hematol. 2000
Apr;79(4):187-97. PubMed PMID: 10834506.
2: Jansen M, Dykstra M, Lee JI, Stables J, Topley P, Knick VC, Mullin
RJ, Duch DS, Smith GK. Effect of purine synthesis inhibition on WiDr
spheroids in vitro or on WiDr or colon 38 tumors in vivo. Complete
growth inhibition but not regression. Biochem Pharmacol. 1994 Mar
15;47(6):1067-78. PubMed PMID: 8147906.
3: Pezzoni G, Grandi M, Biasoli G, Capolongo L, Ballinari D, Giuliani
FC, Barbieri B, Pastori A, Pesenti E, Mongelli N, et al. Biological
profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.
Br J Cancer. 1991 Dec;64(6):1047-50. PubMed PMID: 1764367; PubMed
Central PMCID: PMC1977856.
4: Pharmacologic and clinical studies on n-formyl-sarcolysine. Chinas
Med. 1967 Aug;8:606-23. PubMed PMID: 5588881.
5: SUNG CY, CHU HY, LI CH. PHYSIOLOGIC DISPOSITION OF
N-FORMYL-SARCOLYSINE-C14 IN NORMAL AND TUMOR-BEARING ANIMALS. Chin Med J
(Engl). 1965 Feb;84:84-91. PubMed PMID: 14285313.
6: WU HH, CHOU CC, SUN Y, FENG HY. A PRELIMINARY CLINICAL REPORT ON THE
EFFICACY OF N-FORMYL SARCOLYSIN IN THE TREATMENT OF SOME MALIGNANT
DISEASES. Acta Unio Int Contra Cancrum. 1964;20:357-9. PubMed PMID:
14151928.
7: CHI HC, WANG CK, HAN J. [THE EFFECT OF N-FORMYL-SARCOLYSIN UPON P32
INCORPORATION INTO NUCLEIC ACIDS OF NORMAL TISSUES AND TRANSPLANTABLE
TUMORS.]. Sheng Li Xue Bao. 1963 Sep;26:264-70. Chinese. PubMed PMID:
14089287.
8: HAN J, WANG CK, CHI HC, LI KT, LIU KT, CHANG HY, HO S, FAN LL, LEI
HP. [STUDIES ON ANTITUMOR DRUGS. VIII. THE ANTITUMOR EFFECT OF THE ETHYL
ESTER OF N-FORMYL-SARCOLYSIN- PHENYLALANINE ON EXPERIMENTAL TUMORS.].
Yao Xue Xue Bao. 1963 Aug;10:460-5. Chinese. PubMed PMID: 14081390.
9: JUEI H, CHEN-KANG W, SHIH H, HSIU-CHUAN C, KENG-T'AO L, T'IEN-HSI C,
HUEI-YAN C, LI-LI F. Effect of N-formyl-sarcolysine on experimental
tumors. Chin Med J. 1962 Sep;81:574-84. PubMed PMID: 14029821.
10: JUEI H, CHEN-KANG W, SHIH H, HSIU-CHUAN C, KENG-T'AO L, T'IEN-HSI C,
HUEI-YAN C, LI-LI F. Effect of N-formyl-sarcolysine on experimental
tumors. Chin Med J. 1962 Sep;81:574-84. PubMed PMID: 13957970.
11: HUAN-HSING W, CHI-CH'ANG C, YEN S, HUEI-YING F. Efficacy of n-formyl-sarcolysine
in the treatment of some malignant diseases. Preliminary clinical
report. Chin Med J. 1962 Sep;81:585-98. PubMed PMID: 13955332.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
